GPR123 Inhibitors

GPR123- Inhibitors, predominantly affect the broader GPCR signaling mechanisms. GPCRs can trigger a range of intracellular pathways, and the compounds listed can modulate various components of these cascades, thereby indirectly influencing GPR123 function as it operates through standard GPCR mechanisms.

For instance, Pertussis toxin targets Gi/o proteins, which are critical components in GPCR-mediated intracellular signaling. GDP-β-S operates at a similar level, dampening G-protein activation. U73122 and Chelerythrine Chloride inhibit phospholipase C (PLC) and protein kinase C (PKC) respectively, both of which play roles in downstream GPCR signaling. Kinase inhibitors such as Genistein, PP2, and LY294002 shed light on the intricate kinase networks intertwined with GPCR signaling. Genistein's action on tyrosine kinases, LY294002's influence on PI3K, and PP2's suppression of Src kinases all contribute to modulating the wider GPCR signaling landscape. Similarly, inhibitors like PD98059 and SP600125, which target components of the MAPK pathway, affect a major downstream cascade associated with numerous GPCRs. The cAMP pathway, another pivotal signaling route for GPCRs, is targeted by SQ22536 and H89, which inhibit adenylyl cyclase and PKA, respectively. KN-93, a CaMKII inhibitor, further exemplifies the diverse signaling pathways intersecting with GPCR activity.